Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2012. The report details a specific share repurchase transaction executed on March 13, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 450,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,436.5 pence per share; lowest price paid was 1,428 pence per share.
- Treasury Holdings (Settled): 512,197,927 shares (9.22% of total issued share capital).
- Treasury Holdings (Including Unsettled): 513,447,927 shares (10.18% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,045,296,668 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 450,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.18% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (512,197,927 settled) against the company's latest capitalization table.
- Confirm the percentage of total voting rights represented by Treasury shares (10.18% including unsettled).
- Check the total number of shares in issue excluding Treasury (5,045,296,668) for use in calculating disclosure thresholds under Financial Services Authority rules.
- Review the price range paid (1,428 to 1,436.5 pence) to assess the cost of capital return relative to market prices on March 13, 2012.